Skip to main content

Accelerate your vaccine discovery and development efforts

Maximize your lab’s efficiency with proven methods. Get information quickly, minimize costs, and get the reliable results you need to confidently empower your vaccine discovery and development decisions. Agilent provides the complete breadth of systems, consumables, software, services, and expertise to support these efforts, understanding that every result is time sensitive, and certainty is crucial.

Contact us
×

Contact Us


Reliable, rapid, and high-throughput QC for IVT RNA vaccine development

In vitro-transcribed (IVT) RNA is a breakthrough method in vaccine development enabled by recent advances in mRNA research.  The process begins with the isolation and genome sequencing of a pathogen of interest. A gene encoding a viral epitope mimicking the virus is produced synthetically and the RNA is transcribed in the lab. When introduced into the body, these synthetic RNA sequences instruct cells to produce a viral protein. The viral protein triggers an immune response which trains the body to combat the actual virus. To ensure high quality production of IVT RNA, implementing quality control (QC) at key steps throughput process development is critical. The Agilent Fragment Analyzer systems provide reliable nucleic acid analysis with flexible throughput options.



Research leveraging cell and molecular biology

Explore live cell analysis systems, automated incubators, and molecular characterization platforms to enable antiviral drug discovery.

Learn more

Analytical solutions for mRNA and LNP characterization

Characterize LNP-encapsulated mRNA delivery systems with complete and proven analytical workflows.

Explore methods

Analytical solutions for AAV characterization

Explore analytical methods for characterization of viral delivery systems.

Learn more

Leveraging targeted next-generation sequencing in infectious disease research

Sequencing pathogen genomes can provide mechanistic insights into infectivity and vaccine development.  Using Agilent SureSelect technology, nucleic acid derived from pathogens can be enriched from that of the host cell enabling targeted sequencing to advance your research faster.  



Drive virology research with proven and novel technologies for cell-based assays

Cell-based assays are a valuable tool for understanding pathogenesis and immune responses and can be instrumental for vaccine development.  From basic to antiviral drug research, developing the best assay can be critical to success.  Agilent provides a range of unique technologies for general applications such as virus titrations, viral plaque assays, and multiparametric analysis of cell host responses.





Contact us

Contact us or have us contact you. Please be sure to opt in to receive the latest information from Agilent to help optimize your vaccine characterization methods including applications, educational events, webinars, products, and more.

Contact us
×

Contact Us


For Research Use Only.  Not for use in diagnostic procedures.

RA45561.6344907407, PR7001-3341

×

Contact Us